Portfolio
Portfolio Companies Fund 1
Activaero
Sector: Medical Devices
Country: Germany
Activaero is the leading company in the field of controlled breathing technologies for inhaled therapeutic agents. In March 2014, the company was acquired by Vectura Group for €130 million.
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Apitope
Sector: Immunotherapeutics
Country: United Kingdom / Belgium
Apitope is an established leader in discovery and development of antigen-specific immunotherapeutic peptides focused on autoimmune diseases.
Contacts
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
Stéphane Verdood, Managing Partner Vesalius Biocapital III
Bienca
Sector: Nutrition & food preservation
Country: Belgium
Biotechnological Enzymatic Catalyse - Bienca - develops, produces and commercializes enzymatic systems for food protection. It is one of the first companies in the world to propose bio-mimicry (technology inspired by nature) for food protection.
Contacts
Alain Parthoens, https://www.complix.com/
Complix
Sector: Protein therapeutics
Country: Belgium
Complix is a developer of novel protein therapeutics based on its proprietary Alphabody technology.
Contacts
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
Fovea Pharmaceuticals
Sector: Therapeutics
Country: France
Fovea Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative drug products for disabling diseases of the eye. In October 2009, Fovea was acquired by Sanofi for €370 million in total.
Contacts
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
Genomic Vision
Sector: Molecular Diagnostics
Country: France
Genomic Vision has developed a pioneering approach for genomic analyses called molecular combing technology, which allows the direct visualization of single DNA molecules. The company uses this approach to detect quantitave and qualitative changes in the genome linked to disease.
Contacts
Stéphane Verdood, Managing Partner Vesalius Biocapital III
ProFibrix
Sector: Therapeutics & Drug Delivery
Country: The Netherlands
ProFibrix leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Trade sale to The Medicines for $240 million in August 2013.
Contacts
Alain Parthoens, Managing Partner Vesalius Biocapital III
Promethera
Sector: Cell Therapy
Country: Belgium
Promethere Biosciences is an innovative stem cell therapy company and a spin-off the Université Catholique de Louvain. It‘s mission is to develop novel cell-based products to treat incurable liver disease.
Contacts
Alain Parthoens, Managing Partner Vesalius Biocapital III
Skyline Diagnostics
Sector: Molecular Diagnostics
Country: The Netherlands
Skyline Diagnostics is a molecular diagnostic company developing tests for the classification of patients with blood cancers. The tests are standardized, automated and easy to use, thus allowing for a rapid, personalized treatment of each patient. Written off.
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III
Trinean
Sector: Instrumentation
Country: Belgium
Trinean is a developer and producer of nanoliter spectrophotometers and consumables for the scientific market.
Contacts
Dr. Gaston Matthyssens, Managing Partner Vesalius Biocapital III
Ventaleon
Sector: Drug Delivery
Country: Germany
Ventaleon was established in 2012 as a pulmonary drug development company which specializes in the development of novel antiviral agents applied via inhalation.
Contacts
Dr. Christian Schneider, Managing Partner Vesalius Biocapital III